^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ARID1A mutation

    i
    Other names: ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OS
    Entrez ID:
    8289
    Related biomarkers:
    Mutation
    CNA
    Others
    1d
    Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer. (PubMed, Clin Transl Oncol)
    The interpretable DeepSurv model, integrating multimodal features, enables quantitative survival prediction and risk stratification in advanced NSCLC, facilitating personalized decision-making.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A)
    |
    TP53 mutation • EGFR mutation • PIK3CA mutation • ARID1A mutation • STK11 mutation • MET mutation
    |
    MSK-ACCESS
    6d
    ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, University of California, Irvine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date • Checkpoint inhibition • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    6d
    Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov)
    P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    ARID1A mutation • EZH2 mutation
    |
    HH2853
    6d
    DDRiver Solid Tumours 301: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) (clinicaltrials.gov)
    P1, N=161, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • ATRX (ATRX Chromatin Remodeler)
    |
    ATM mutation • ARID1A mutation
    |
    Zejula (niraparib) • tuvusertib (M1774)
    7d
    A phase II clinical trial of epalolitoporvorellimab (QL1706) in combination with fruquintinib for the treatment of immunocompetent pMMR/MSS metastatic colorectal cancer that has failed second- or higher lines of therapy. (ChiCTR2500112464)
    P2, N=18, Not yet recruiting, Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • ARID1A (AT-rich interaction domain 1A) • POLE (DNA Polymerase Epsilon) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • POLD1 (DNA Polymerase Delta 1)
    |
    ARID1A mutation
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab)
    8d
    Harnessing AACR Project GENIE to Define the Molecular Features of Desmoplastic Small Round Cell Tumor. (PubMed, Curr Issues Mol Biol)
    Our data highlights mutational variation across demographic cohorts. These patterns are vital to future studies into identifying diagnostic markers or therapeutic targets.
    Journal
    |
    TP53 (Tumor protein P53) • ARID1A (AT-rich interaction domain 1A) • FGFR4 (Fibroblast growth factor receptor 4) • KMT2C (Lysine Methyltransferase 2C) • WT1 (WT1 Transcription Factor) • EP300 (E1A binding protein p300) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • ANKRD1 (Ankyrin Repeat Domain 1) • TRAF1 (TNF Receptor Associated Factor 1) • PCLO (Piccolo Presynaptic Cytomatrix Protein)
    |
    TP53 mutation • ATM mutation • ARID1A mutation
    11d
    Comprehensive Genomic Characterization of 102 Cervical Adenocarcinoma Tumors. (PubMed, Medicina (Kaunas))
    This study validates the primary drivers of cervical adenocarcinoma and reveals novel findings, including notable racial disparities in TP53 mutation frequency and unique patterns of co-occurring mutations. These findings highlight the genomic heterogeneity of the disease and suggest that ancestry and tumor evolution may influence its molecular pathogenesis, offering potential avenues for the development of targeted therapies and personalized biomarkers.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • BCL6 (B-cell CLL/lymphoma 6) • MSH2 (MutS Homolog 2)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • PIK3CA mutation • ATM mutation • ARID1A mutation • STK11 mutation
    12d
    A case of endometrioid carcinoma of the endometrium that progressed to lethal neuroendocrine carcinoma as a result of TMEM178B-BRAF fusion. (PubMed, Int Cancer Conf J)
    Gene panel testing identified TMEM178B-BRAF fusion and subclonal PIK3CA mutations in the liver metastasis, in addition to ARID1A and CTNNB1 mutations that were shared with the endometrial tumour. This is the first report of an endometrioid carcinoma transforming into a high-grade neuroendocrine tumour associated with TMEM178B-BRAF fusion.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SYP (Synaptophysin)
    |
    BRAF mutation • PIK3CA mutation • ARID1A mutation • ER negative • BRAF fusion
    15d
    Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis. (PubMed, J Mol Med (Berl))
    Here we show that combination of niraparib and lenvatinib exhibits significant synergistic inhibitory effects against platinum-resistant OCCC cell lines, xenografts, patient-derived tumoroid (PDT) models, and prolonged survival in the platinum-refractory patient-derived xenograft (PDX) model. RNA sequencing revealed that the most differentially expressed genes in PDX models treated with this combination were associated with structural ribosomal components. This combination suppresses Src phosphorylation, NPM1 expression, and ribosomal protein levels in OCCC.
    Journal • PARP Biomarker
    |
    NPM1 (Nucleophosmin 1) • ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Lenvima (lenvatinib) • Zejula (niraparib)
    18d
    Distinct Molecular and Prognostic Profiles of Left- and Right-Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations. (PubMed, Cancer Med)
    These findings reveal criticalmolecular and prognostic differences between LCC and RCC and highlight SMAD4 and SETD2 asimportant prognostic biomarkers, suggesting the potential value of location-and mutation-guided precision therapies in CRC.
    Retrospective data • Journal • Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • PRDM1 (PR/SET Domain 1) • PI3K (Phosphoinositide 3-kinases)
    |
    BRAF mutation • ARID1A mutation
    18d
    Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability. (PubMed, AIDS)
    Together, these results highlight distinct tumorigenic mechanisms in HIV+ DLBCL and underscore the need for mutational profiling of HIV+ DLBCL cohorts worldwide to identify biomarkers and therapeutic targets.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • KMT2D (Lysine Methyltransferase 2D) • MSH2 (MutS Homolog 2) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)
    |
    PTEN mutation • ARID1A mutation • NRAS Q61
    27d
    Divergent evolution of hepatocellular carcinoma genomes in chimpanzees and humans. (PubMed, Evol Med Public Health)
    Divergent evolutionary patterns highlight species-specific oncogenic routes while underscoring conserved pathways. Comparative primate cancer genomics offers novel insights into cancer evolution, biomarkers, and therapeutic targets.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TSC2 (TSC complex subunit 2) • FAT1 (FAT atypical cadherin 1) • VIM (Vimentin) • FAT4 (FAT Atypical Cadherin 4) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    TP53 mutation • TMB-H • ARID1A mutation